EP3030255
Ný ónæmismeðferð við þónokkrum æxlistegundum, svo sem lungnakrabbameini, þar á meðal NSCLC-lungnakrabbameini
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
4.8.2014EP published:
9.10.2019EP application number:
14750175.3
EP translation filed:
2.1.2020Grant published:
15.2.2020EPO information:
European Patent Register
Max expiry date:
3.8.2034Expiry date:
3.8.2024
Title:
NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC
Timeline
Today
4.8.2014EP application
9.10.2019EP Publication
2.1.2020Translation submitted
15.2.2020Registration published
3.8.2024Expires
Owner
Name:
Immatics Biotechnologies GmbHAddress:
Paul-Ehrlich-Strasse 15, 72076, Tübingen, DE
Inventor
Name:
WEINSCHENK, ToniAddress:
Aichwald, DE
Name:
WALTER, SteffenAddress:
Reutlingen, DE
Name:
FRITSCHE, JensAddress:
Dusslingen, DE
Name:
SONG, ColetteAddress:
Ostfildern, DE
Name:
SINGH, HarpreetAddress:
München, DE
Agent
Name:
Boehmert & BoehmertAddress:
Pettenkoferstrasse 20-22, DE
Priority
Number:
201313987Date:
5.8.2013Country:
GB
Number:
201361862213 PDate:
5.8.2013Country:
US
Number:
201403297Date:
25.2.2014Country:
GB
Classification
Categories:
A61K 38/17, A61K 39/00, C07K 7/06, C12N 5/0783, C07K 7/08
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 17.8.2020
Expires: 3.8.2021
Payer: Patice ehf.
Number: 8
Paid: 17.8.2021
Expires: 3.8.2022
Payer: Patice ehf.
Number: 9
Paid: 17.8.2022
Expires: 3.8.2023
Payer: Patice ehf.
Number: 10
Paid: 28.8.2023
Expires: 3.8.2024
Payer: Árnason Faktor ehf.